89,892 Shares in Insulet Corporation $PODD Purchased by Corient Private Wealth LP

Key Points

• Corient Private Wealth LP purchased 89,892 Insulet shares worth approximately $13.7 million, establishing a 0.13% stake. Other major institutions, including BlackRock, Norges Bank and Arrowstreet Capital, also increased or initiated positions.
• Insulet reported strong quarterly results, with revenue up 23.5% year over year to $801.7 million and earnings of $1.66 per share versus the $1.47 consensus estimate.
• Analyst sentiment remains mixed: the consensus rating is “Hold”, while several firms recently lowered price targets; shares opened at $145.13, well below the 52-week high of $354.88.

Corient Private Wealth LP purchased a new stake in shares of Insulet Corporation (NASDAQ:PODD - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 89,892 shares of the medical instruments supplier's stock, valued at approximately $13,686,000. Corient Private Wealth LP owned 0.13% of Insulet at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of PODD. BlackRock Inc. bought a new position in shares of Insulet during the second quarter valued at approximately $1,018,582,000. Norges Bank bought a new stake in shares of Insulet in the 4th quarter worth approximately $300,794,000. Arrowstreet Capital Limited Partnership grew its stake in shares of Insulet by 462.7% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares during the last quarter. Man Group plc purchased a new stake in shares of Insulet in the 2nd quarter worth approximately $78,746,000. Finally, Bank of America Corp DE bought a new position in Insulet during the 2nd quarter valued at approximately $64,921,000.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Stifel Nicolaus cut their price objective on shares of Insulet from $225.00 to $180.00 and set a "buy" rating on the stock in a research report on Thursday, August 6th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $152.00 target price (down from $275.00) on shares of Insulet in a research note on Thursday, August 6th. Robert W. Baird set a $175.00 price target on shares of Insulet in a report on Thursday, August 6th. The Goldman Sachs Group reissued a "buy" rating and set a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Finally, Sanford C. Bernstein decreased their price objective on shares of Insulet from $200.00 to $175.00 and set an "outperform" rating for the company in a report on Thursday, August 6th. Fourteen analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $195.40.

Insulet Stock Performance

Shares of NASDAQ PODD opened at $145.13 on Friday. The firm's 50-day moving average price is $154.46 and its 200-day moving average price is $181.15. Insulet Corporation has a 52-week low of $126.40 and a 52-week high of $354.88. The company has a market cap of $10.06 billion, a PE ratio of 27.13, a PEG ratio of 1.14 and a beta of 1.10. The company has a quick ratio of 1.83, a current ratio of 2.48 and a debt-to-equity ratio of 0.65.

Insulet (NASDAQ:PODD - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating the consensus estimate of $1.47 by $0.19. The firm had revenue of $801.70 million during the quarter, compared to analysts' expectations of $787.39 million. Insulet had a net margin of 12.29% and a return on equity of 29.29%. The firm's quarterly revenue was up 23.5% on a year-over-year basis. During the same period in the previous year, the company earned $1.17 earnings per share. Insulet has set its FY 2026 guidance at 6.460- EPS. As a group, analysts anticipate that Insulet Corporation will post 6.51 EPS for the current year.

Insiders Place Their Bets

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company's stock, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.36% of the company's stock.

More Insulet News

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
• Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
• Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company's core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet's products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company's product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source